Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 14Terminated 9Recruiting 4Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

methylnaltrexone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Opioid-Induced Constipation × Clear all
NCT00858754 2019-11-29

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Bausch Health Americas, Inc.

Phase 4 Withdrawn
Other

Opioid-Induced Constipation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡